News|Articles|April 22, 2026

Concomitant Influenza and Pertussis Vaccination in Pregnancy Shows No Increased Risk

Fact checked by: Justin Mancini

Results from a large population-based study found that receiving influenza and pertussis vaccines on the same day during pregnancy does not increase the risk of adverse maternal, birth, or neonatal outcomes compared with pertussis vaccination alone.

Safety concerns remain one of the most persistent barriers to vaccination during pregnancy, particularly when multiple vaccines are recommended within a relatively short time frame. As maternal immunization strategies expand to include protection against influenza, pertussis, COVID-19, and respiratory syncytial virus, questions about the safety of administering more than 1 vaccine at the same visit have become increasingly relevant.

A large population-based cohort study conducted in Australia offers important reassurance. Researchers analyzed data from 13,918 singleton pregnancies, comparing outcomes among women who received concomitant influenza and pertussis vaccines at 20 weeks’ gestation or later with those who received the pertussis vaccine alone. The groups were carefully matched based on vaccination timing, gestational age, and maternal age to ensure a robust comparison.

The findings showed no evidence of increased risk associated with concomitant vaccination. Preterm birth occurred in 3.8% of women who received both vaccines simultaneously compared with 4.4% in the control group. After statistical adjustment, this difference was not significant, indicating that receiving both vaccines on the same day does not elevate preterm birth risk.

No Increase in Maternal or Neonatal Complications

The study also examined a range of neonatal outcomes among term births. Rates of children born small for gestational age were slightly lower in the concomitant vaccination group (8.8%) compared with the control group (9.9%), whereas rates of low birth weight were nearly identical (1.7% vs 1.6%). Again, none of these differences reached statistical significance.

What You Need to Know

Concomitant influenza and pertussis vaccination during pregnancy was not associated with higher rates of preterm birth, low birth weight, or newborns small for gestational age.

Maternal complications and neonatal outcomes were similar between women receiving simultaneous vaccines and those receiving pertussis vaccine alone.

The findings support same-day vaccination as a practical strategy to improve coverage during pregnancy without compromising safety.

Stillbirths were rare, with only 17 cases observed across the entire matched cohort, limiting the ability to draw meaningful comparisons. However, the low number itself reinforces the overall safety profile observed in both groups.

In addition to primary outcomes, researchers assessed several maternal complications, including preeclampsia, antepartum and postpartum hemorrhage, chorioamnionitis, prelabor rupture of membranes, and preterm labor. No differences were observed between the concomitant vaccination group and the control group for any of these outcomes.

To strengthen confidence in the findings, the analysis adjusted for a range of potential confounders, including socioeconomic status, smoking during pregnancy, and COVID-19 vaccination status. Sensitivity analyses—such as alternative matching approaches and exclusion of certain subgroups—yielded consistent results, underscoring the robustness of the conclusions.

Reference
Sonneveld N, Reekie J, Deng L, O’Grady K, Macartney K, Liu B. Coadministered influenza- and pertussis-containing vaccines in pregnant women. JAMA Netw Open. 2026;9(4):e267551. doi:10.1001/jamanetworkopen.2026.7551

Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.